Gemini to initiate CLARITY dry AMD disease registry and study
Gemini Therapeutics announced a disease registry and natural history study to identify and characterize disease progression in patients with non-central geographic atrophy secondary to dry age-related macular degeneration, according to a press release.
Thousands of subjects will be genetically screened to assess genetic loci across high-risk genetic variants associated with dry AMD, and hundreds will be enrolled in one of two studies based on genetic criteria, the release said.
CLARITY1 will evaluate long-term clinical outcomes and disease progression in those who are carriers of functionally consequential genetic variants, and CLARITY2 is a 2-year natural history study evaluating clinical characteristics and disease progression in subjects with high-risk genetic variants in complement factor H.
“At Gemini, we see a future where dry AMD therapeutics will be selected for each patient based on what is written into their DNA, and the CLARITY studies are foundational for this future,” Gemini President and CEO James McLaughlin said in the release.